Dermatology
Case Report
Three Cases of Pityriasis rubra pilaris Successfully Treated with Cyclosporin AUsuki K. · Sekiyama M. · Shimada T. · Shimada S. · Kanzaki T.Department of Dermatology, Kagoshima University Faculty of Medicine, Kagoshima, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: July 06, 2000
Issue release date: 2000
Number of Print Pages: 4
Number of Figures: 5
Number of Tables: 1
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
Background: Pityriasis rubra pilaris (PRP) is reported to respond poorly to cyclosporin A (CsA). Objective: We attempted to determine the efficacy of CsA in the treatment of classic adult-type PRP. Methods: Three patients with classic adult-type PRP were treated with 5 mg/kg/day CsA. Results: A sustained clinical response was achieved within 2–4 weeks of therapy. Relapses were noted when the CsA dose was decreased to 1.2 mg/kg/day. Conclusion: CsA should be considered in the treatment of classical adult-type PRP.
© 2000 S. Karger AG, Basel
Related Articles:
References
- Griffiths WAD: Pityriasis rubra pilaris. Clin Exp Dermatol 1980;5:105–112.
- Ho VC, Lui H, McLean DI: Cyclosporin in nonpsoriatic dermatoses. J Am Acad Dermatol 1990;23:1248–1259.
-
Griffiths WAD, Leigh IM, Marks R: Disorders of keratinization; in Champion RH, Burton JL, Ebling FJG (eds): Textbook of Dermatology, ed 5. Oxford, Blackwell Scientific Publications, 1992, vol 2, pp 1325–1390.
- Cohen PR, Prystowsky JH: Pityriasis rubra pilaris: A review of diagnosis and treatment. J Am Acad Dermatol 1989;20:801–807.
- Mayer P, Van Voorst Vader PC: Lack of effect of cyclosporin A in pityriasis rubra pilaris. Acta Derm Venereol 1989;69:272.
-
Ghanzi A, Laso-Dosal F: Cyclosporin A and pityriasis rubra pilaris. Acta Derm Venereol 1990;70:181.
- Oxholm A, Thomsen K, Menne T: Squamous cell carcinomas in relation to cyclosporin therapy of nonmalignant skin disorders. Acta Derm Venereol 1989;69:89–90.
- Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Griffiths CE, Cooper KD, Voorhees JJ: Oral cyclosporin in the treatment of inflammatory and noninflammatory dermatoses: A clinical and immunopathologic analysis. Arch Dermatol 1990;126:339–350.
-
Rosenbach A, Lowe NJ: Pityriasis rubra pilaris and cyclosporin. Arch Dermatol 1993;129:1346–1348.
External Resources
-
Furue M, Gaspari AA, Katz S: I. The effect of cyclosporin A on epidermal cells. II. Cyclosporin A inhibits proliferation of normal and transformed keratinocytes. J Invest Dermatol 1998;90:796–800.
-
Ootuyama M, Maruyama T, Morohashi M: Histopathological and immunohistochemical studies of pityriasis rubra pilaris. Proc 9th Conf Disord Keratinization, Nippon Roche Co, Tokyo, 1994, pp 47–49.
- Toti P, Pellegrino M, Villanova M, Miracco C, Bartolommei S, Andressi L: Altered expression of the α2-laminin chain in psoriatic skin: The effect of treatment with cyclosporin. Br J Dermatol 1998;139:375–379.
- Sanchez RM, Fuentes CG, Creus L, Salleras M, Umbert P: Pityriasis rubra pilaris and HIV infection: A part of the spectrum of HIV-associated follicular syndrome. Br J Dermatol 1995;133:818–819.
- Miralles ES, Nunez M, De Las Heras ME, Perez B, Moreno R, Ledo A: Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol 1995;133:990–993.
Article / Publication Details
Published online: July 06, 2000
Issue release date: 2000
Number of Print Pages: 4
Number of Figures: 5
Number of Tables: 1
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
